다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Nature reviews. Drug discovery, v.7 no.3, 2008년, pp.255 - 270
Rautio, Jarkko (Department of Pharmaceutical Chemistry, University of Kuopio, PO Box 1627, FI-70211 Kuopio, Finland.) , Kumpulainen, Hanna (Department of Pharmaceutical Chemistry, University of Kuopio, PO Box 1627, FI-70211 Kuopio, Finland.) , Heimbach, Tycho (Novartis Pharmaceuticals, One Health Plaza, East Hanover, New Jersey 07936-1080, USA.) , Oliyai, Reza (Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, USA.) , Oh, Dooman (Pharmacokinetics and Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA.) , Järvinen, Tomi (Department of Pharmaceutical Chemistry, University of Kuopio, PO Box 1627, FI-70211 Kuopio, Finland.) , Savolainen, Jouko (Fennopharma Ltd, Microkatu 1, FI-70210, Kuopio, Finland.)
AI-Helper
Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for i...
J. Pharm. Sci. S Venkatesh 89 145 2000 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6 Venkatesh, S. & Lipper, R. A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89, 145-154 (2000).
V Stella 221 2006 Optimizing the “Drug-Like” Properties of Leads in Drug Discovery 10.1007/978-0-387-44961-6_10 Stella, V. in Optimizing the “Drug-Like” Properties of Leads in Drug Discovery (eds Borchardt, R., Hageman, M., Stevens, J., Kerns, E. & Thakker, D.) 221-242 (Springer, New York, 2006).
Curr. Drug Metab. K Beaumont 4 461 2003 10.2174/1389200033489253 Beaumont, K., Webster, R., Gardner, I. & Dack, K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 4, 461-485 (2003). A comprehensive review on ester prodrugs for improved oral absorption.
J. Med. Chem. P Ettmayer 47 2393 2004 10.1021/jm0303812 Ettmayer, P., Amidon, G. L., Clement, B. & Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47, 2393-2404 (2004).
T Jarvinen 733 2005 Drug Discovery Handbook 10.1002/0471728780.ch17 Jarvinen, T., Rautio, J., Masson, M. & Loftsson, T. in Drug Discovery Handbook (ed. Gad, S.) 733-796 (John Wiley & Sons, Hoboken, 2005).
Expert Opin. Ther. Pat. VJ Stella 14 277 2004 10.1517/13543776.14.3.277 Stella, V. J. Prodrugs as therapeutics. Expert Opin. Ther. Pat. 14, 277-280 (2004). An evaluation of prodrug patents and research through 2004.
Biochem. Pharmacol. B Testa 68 2097 2004 10.1016/j.bcp.2004.07.005 Testa, B. Prodrug research: futile or fertile? Biochem. Pharmacol. 68, 2097-2106 (2004).
V Stella 2007 Prodrugs: Challenges and Rewards 10.1007/978-0-387-49785-3 Stella, V. et al. Prodrugs: Challenges and Rewards (AAPS Press/Springer, New York, 2007). An excellent book of all aspects of prodrugs.
Adv. Drug Deliv. Rev. VJ Stella 59 677 2007 10.1016/j.addr.2007.05.013 Stella, V. J. & Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 59, 677-694 (2007). A recent review on water-soluble prodrugs.
J. Control. Release PK Kiptoo 113 137 2006 10.1016/j.jconrel.2006.04.003 Kiptoo, P. K., Hamad, M. O., Crooks, P. A. & Stinchcomb, A. L. Enhancement of transdermal delivery of 6-b-naltrexol via a codrug linked to hydroxybupropion. J. Control. Release 113, 137-145 (2006).
J. Med. Chem. J Leppanen 45 1379 2002 10.1021/jm010980d Leppanen, J. et al. Design and synthesis of a novel L-DOPA-entacapone codrug. J. Med. Chem. 45, 1379-1382 (2002).
Pharmacol. Ther. RE Notari 14 25 1981 10.1016/0163-7258(81)90009-7 Notari, R. E. Prodrug design. Pharmacol. Ther. 14, 25-53 (1981).
J. Pharm. Sci. AA Sinkula 64 181 1975 10.1002/jps.2600640203 Sinkula, A. A. & Yalkowsky, S. H. Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci. 64, 181-210 (1975).
Drugs VJ Stella 29 455 1985 10.2165/00003495-198529050-00002 Stella, V. J., Charman, W. N. & Naringrekar, V. H. Prodrugs. Do they have advantages in clinical practice? Drugs 29, 455-473 (1985).
Pharmacol. Ther. N Bodor 76 1 1997 10.1016/S0163-7258(97)00098-3 Bodor, N. & Buchwald, P. Drug targeting via retrometabolic approaches. Pharmacol. Ther. 76, 1-27 (1997).
Med. Res. Rev. N Bodor 20 58 2000 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X Bodor, N. & Buchwald, P. Soft drug design: general principles and recent applications. Med. Res. Rev. 20, 58-101 (2000).
Curr. Med. Chem. T Thorsteinsson 10 1129 2003 10.2174/0929867033457520 Thorsteinsson, T., Loftsson, T. & Masson, M. Soft antibacterial agents. Curr. Med. Chem. 10, 1129-1136 (2003).
Bioorg. Med. Chem. Lett. S Majumdar 16 3590 2006 10.1016/j.bmcl.2006.03.061 Majumdar, S. & Sloan, K. B. Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs. Bioorg. Med. Chem. Lett. 16, 3590-3594 (2006).
Mini Rev. Med. Chem. S Peyrottes 4 395 2004 10.2174/1389557043404007 Peyrottes, S. et al. SATE pronucleotide approaches: an overview. Mini Rev. Med. Chem. 4, 395-408 (2004).
Curr. Opin. Investig. Drugs JR Fozard 1 86 2000 Fozard, J. R. BP-294 Ste Civile Bioprojet. Curr. Opin. Investig. Drugs 1, 86-89 (2000).
J. Pharmacol. Exp. Ther. A Rouleau 281 1085 1997 Rouleau, A. et al. Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug. J. Pharmacol. Exp. Ther. 281, 1085-1094 (1997).
10.1016/j.ijpharm.2006.11.055 Simplicio, A. L., Clancy, J. M. & Gilmer, J. F. β-Aminoketones as prodrugs with pH-controlled activation. Int. J. Pharm. 208-214 (2006).
Adv. Drug Deliv. Rev. MD Taylor 19 131 1996 10.1016/0169-409X(95)00104-F Taylor, M. D. Improved passive oral drug delivery via prodrugs. Adv. Drug Deliv. Rev. 19, 131-148 (1996).
J. Pharm. Sci. BM Liederer 95 1177 2006 10.1002/jps.20542 Liederer, B. M. & Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95, 1177-1195 (2006).
Res. Commun. Chem. Pathol. Pharmacol. D Ecobichon 3 629 1972 Ecobichon, D. Relative amounts of hepatic and renal carboxylesterase in mammalian species. Res. Commun. Chem. Pathol. Pharmacol. 3, 629-636 (1972).
Drug Metab. Dispos. LH Pao 33 395 2005 10.1124/dmd.104.002451 Pao, L. H., Hsiong, C. H., Hu, O. Y., Wang, J. J. & Ho, S. T. In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine. Drug Metab. Dispos. 33, 395-402 (2005).
Int. J. Pharm. T Heimbach 261 81 2003 10.1016/S0378-5173(03)00287-4 Heimbach, T. et al. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int. J. Pharm. 261, 81-92 (2003).
T Heimbach 155 2007 Prodrugs: Challenges and Rewards Heimbach, T., Fleisher, D. & Kaddoumi, A. in Prodrugs: Challenges and Rewards. Part 1 (eds. Stella, V. et al.) 155-212 (AAPS Press/Springer, New York, 2007).
R McComb 1979 Alkaline Phosphatase 10.1007/978-1-4613-2970-1 McComb, R., Bowers, G. & Posen, S. Alkaline Phosphatase (Plenum Press, New York and London, 1979).
Curr. Med. Chem. PM Potter 13 1045 2006 10.2174/092986706776360969 Potter, P. M. & Wadkins, R. M. Carboxylesterases - detoxifying enzymes and targets for drug therapy. Curr. Med. Chem. 13, 1045-1054 (2006).
Pharm. Res. CY Yang 16 1331 1999 10.1023/A:1018982505021 Yang, C. Y., Dantzig, A. H. & Pidgeon, C. Intestinal peptide transport systems and oral drug availability. Pharm. Res. 16, 1331-1343 (1999).
Eur. J. Pharm. Sci. B Steffansen 21 3 2004 10.1016/j.ejps.2003.10.010 Steffansen, B. et al. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur. J. Pharm. Sci. 21, 3-16 (2004).
Biochemistry A Jousserandot 37 17179 1998 10.1021/bi981175c Jousserandot, A. et al. Microsomal cytochrome P450 dependent oxidation of N-hydroxyguanidines, amidoximes, and ketoximes: mechanism of the oxidative cleavage of their C=N (OH) bond with formation of nitrogen oxides. Biochemistry 37, 17179-17191 (1998).
J. Med. Chem. H Kumpulainen 49 1207 2006 10.1021/jm0510124 Kumpulainen, H. et al. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. J. Med. Chem. 49, 1207-1211 (2006).
Chem. Res. Toxicol. FP Guengerich 14 611 2001 10.1021/tx0002583 Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611-650 (2001).
Chem. Rev. B Meunier 104 3947 2004 10.1021/cr020443g Meunier, B., de Visser, S. P. & Shaik, S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 104, 3947-3980 (2004).
Drug Metab. Rev. B Clement 34 565 2002 10.1081/DMR-120005643 Clement, B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab. Rev. 34, 565-579 (2002).
Pharm. Res. GL Amidon 12 413 1995 10.1023/A:1016212804288 Amidon, G. L., Lennernas, H., Shah, V. P. & Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995). An introduction to the BCS.
B Aungst 339 2007 Prodrugs: Challenges and Rewards 10.1007/978-0-387-49785-3_8 Aungst, B. & Matz, N. in Prodrugs: Challenges and Rewards. Part 1 (eds. Stella, V. J. et al.) 339-355 (AAPS Press/Springer, New York, 2007).
J. Med. Chem. MR Harnden 32 1738 1989 10.1021/jm00128a012 Harnden, M. R., Jarvest, R. L., Boyd, M. R., Sutton, D. & Vere Hodge, R. A. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J. Med. Chem. 32, 1738-1743 (1989).
Drug Metab. Dispos. M Nakamura 34 369 2006 10.1124/dmd.105.006213 Nakamura, M. et al. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of MGS0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarb oxylic acid), a potent metabotropic glutamate receptor antagonist. Drug Metab. Dispos. 34, 369-374 (2006).
Nucleosides Nucleotides Nucleic Acids EJ Eisenberg 20 1091 2001 10.1081/NCN-100002496 Eisenberg, E. J., He, G.-X. & Lee, W. A. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids 20, 1091-1098 (2001).
Drugs Future J-T Hwang 29 163 2004 10.1358/dof.2004.029.02.780100 Hwang, J.-T. & Choi, J.-R. Novel phosphonate nucleosides as antiviral agents. Drugs Future 29, 163-177 (2004).
Drug Metab. Dispos. L Naesens 20 747 1992 Naesens, L., Balzarini, J. & De Clercq, E. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Metab. Dispos. 20, 747-752 (1992).
J. Chromatogr. JW Russell 572 321 1991 10.1016/0378-4347(91)80498-2 Russell, J. W., Marrero, D., Whiterock, V. J., Klunk, L. J. & Starrett, J. E. Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 572, 321-326 (1991).
Starrett, J. E. Jr, Mansuri, M. M., Martin, J. C., Tortolani, D. R. & Bronson, J. J. Prodrugs of phosphonates. CA2051239 (1992).
J. Pharm. Biomed. Anal. E Deconinck 39 1021 2005 10.1016/j.jpba.2005.05.034 Deconinck, E. et al. Prediction of gastro-intestinal absorption using multivariate adaptive regression splines. J. Pharm. Biomed. Anal. 39, 1021-1030 (2005).
Antiviral Res. JE Starrett Jr 19 267 1992 10.1016/0166-3542(92)90084-I Starrett, J. E. Jr, Tortolani, D. R., Hitchcock, M. J., Martin, J. C. & Mansuri, M. M. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 19, 267-273 (1992).
Drug Metab. Dispos. J-P Shaw 25 362 1997 Shaw, J.-P. et al. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25, 362-366 (1997).
Bioorg. Med. Chem. A Yasuhara 14 4193 2006 10.1016/j.bmc.2006.01.060 Yasuhara, A. et al. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg. Med. Chem. 14, 4193-4207 (2006).
H van De Waterbeemd 51 2001 Pharmacokinetic Optimization in Drug Research 10.1002/9783906390437.ch4 van De Waterbeemd, H. & Smith, D. A. in Pharmacokinetic Optimization in Drug Research (eds Testa, B., Van De Waterbeemd, H., Folkers, G. & Guy, R.) 51-116 (Verlag Helvetica Chimica Acta and Wiley-VCH, Ochsenfurt-Hohenstad, 2001).
J. Pharm. Pharmacol. H Lennernas 55 429 2003 10.1211/002235702973 Lennernas, H. Intestinal drug absorption and bioavailability: beyond involvement of single transport function. J. Pharm. Pharmacol. 55, 429-433 (2003).
J. Med. Chem. H van De Waterbeemd 44 1313 2001 10.1021/jm000407e van De Waterbeemd, H., Smith, D. A., Beaumont, K. & Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44, 1313-1333 (2001).
Pharmacol. Ther. I Cascorbi 112 457 2006 10.1016/j.pharmthera.2006.04.009 Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473 (2006).
Int. J. Toxicol. S Choudhuri 25 231 2006 10.1080/10915810600746023 Choudhuri, S. & Klaassen, C. D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231-259 (2006).
Expert Opin. Drug Deliv. S Katragadda 2 683 2005 10.1517/17425247.2.4.683 Katragadda, S., Budda, B., Anand, B. S. & Mitra, A. K. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin. Drug Deliv. 2, 683-705 (2005).
Int. J. Pharm. R Jain 303 8 2005 10.1016/j.ijpharm.2005.06.017 Jain, R. et al. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 303, 8-19 (2005).
Mol. Pharm. R Jain 1 290 2004 10.1021/mp049952s Jain, R., Majumdar, S., Nashed, Y., Pal, D. & Mitra, A. K. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol. Pharm. 1, 290-299 (2004).
Pharm. Res. T Tanino 24 555 2007 10.1007/s11095-006-9171-6 Tanino, T. et al. Paclitaxel-2′-ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. Pharm. Res. 24, 555-565 (2007).
Am. Pharm. Rev. C Lipinski 5 82 2002 Lipinski, C. Poor solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5, 82-85 (2002).
C Lipinski 93 2004 Biotechnology: Pharmaceutical Aspects (Pharmaceutical Profiling in Drug Discovery for Lead Selection) Lipinski, C. in Biotechnology: Pharmaceutical Aspects (Pharmaceutical Profiling in Drug Discovery for Lead Selection) (eds Borchardt, R. T. et al.) 93-125 (AAPS, Virgina, 2004).
Clin. Pharmacol. Ther. DE Duggan 21 326 1977 10.1002/cpt1977213326 Duggan, D. E., Hare, L. E., Ditzler, C. A., Lei, B. W. & Kwan, K. C. The disposition of sulindac. Clin. Pharmacol. Ther. 21, 326-335 (1977).
Biochem. Pharmacol. DE Duggan 27 2311 1978 10.1016/0006-2952(78)90137-5 Duggan, D. E., Hooke, K. F., Noll, R. M., Hucker, H. B. & Van Arman, C. G. Comparative disposition of sulindac and metabolites in five species. Biochem. Pharmacol. 27, 2311-2320 (1978).
Adv. Drug Res. T Shen 12 90 1977 Shen, T. & Winter, C. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv. Drug Res. 12, 90-295 (1977).
Clin. Pharmacokinet. NM Davies 32 437 1997 10.2165/00003088-199732060-00002 Davies, N. M. & Watson, M. S. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin. Pharmacokinet. 32, 437-459 (1997).
Yakuri to Chiryo H Masuda 26 809 1998 Masuda, H., Ikeda, K., Nagamachi, N., Nagayama, S. & Kawaguchi, Y. Metabolic fate of TAT-59. (4th report): species difference, dose response and protein binding. Yakuri to Chiryo 26, 809-828 (1998) (in Japanese).
Eur. J. Clin. Pharmacol. PO Gunnarsson 26 113 1984 10.1007/BF00546718 Gunnarsson, P. O., Andersson, S. B., Johansson, S. A., Nilsson, T. & Plym-Forshell, G. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. Eur. J. Clin. Pharmacol. 26, 113-119 (1984).
Pharm. Res. T Heimbach 20 848 2003 10.1023/A:1023827017224 Heimbach, T. et al. Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res. 20, 848-856 (2003). A guidance for parent-drug selection when employing the phosphate prodrug approach for oral delivery.
Gan To Kagaku Ryoho Y Nomura 25 553 1998 Nomura, Y. et al. Phase I study of TAT-59 (a new antiestrogen) in breast cancer. Gan To Kagaku Ryoho 25, 553-561 (1998) (in Japanese).
Clin. Pharmacokinet. MB Wire 45 137 2006 10.2165/00003088-200645020-00002 Wire, M. B., Shelton, M. J. & Studenberg, S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45, 137-168 (2006).
Drugs TM Chapman 64 2101 2004 10.2165/00003495-200464180-00014 Chapman, T. M., Plosker, G. L. & Perry, C. M. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 64, 2101-2124 (2004).
Antimicrob. Agents Chemother. ES Furfine 48 791 2004 10.1128/AAC.48.3.791-798.2004 Furfine, E. S. et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48, 791-798 (2004).
VJ Stella 3 2007 Prodrugs: Challenges and Rewards 10.1007/978-0-387-49785-3 Stella, V. J. in Prodrugs: Challenges and Rewards. Part 1 (eds Stella, V. J. et al.) 3-33 (AAPS Press/Springer, New York, 2007).
Pharm. Res. JP Shaw 14 1824 1997 10.1023/A:1012108719462 Shaw, J. P. et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14, 1824-1829 (1997).
M Fardis 647 2007 Prodrugs: Challenges and Rewards Fardis, M. & Oliyai, R. in Prodrugs: Challenges and Rewards. Part 2 (eds Stella, V. J. et al.) 647-657 (AAPS Press/Springer, New York, 2007).
Clin. Infect. Dis. JE Gallant 37 944 2003 10.1086/378068 Gallant, J. E. & Deresinski, S. Tenofovir disoproxil fumarate. Clin. Infect. Dis. 37, 944-950 (2003).
Drugs T Chapman 63 1597 2003 10.2165/00003495-200363150-00006 Chapman, T., McGavin, J. & Noble, S. Tenofovir disoproxil fumarate. Drugs 63, 1597-1608 (2003).
Drugs T Dando 63 2215 2003 10.2165/00003495-200363200-00007 Dando, T. & Plosker, G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 63, 2215-2234 (2003).
Drugs S Noble 58 479 1999 10.2165/00003495-199958030-00010 Noble, S. & Goa, K. L. Adefovir dipivoxil. Drugs 58, 479-487 (1999).
Drugs A Bardsley-Elliot 58 851 1999 10.2165/00003495-199958050-00007 Bardsley-Elliot, A. & Noble, S. Oseltamivir. Drugs 58, 851-860 (1999).
Expert Opin. Pharmacother. KE Doucette 2 1671 2001 10.1517/14656566.2.10.1671 Doucette, K. E. & Aoki, F. Y. Oseltamivir: a clinical and pharmacological perspective. Expert Opin. Pharmacother. 2, 1671-1683 (2001).
Drugs K McClellan 61 263 2001 10.2165/00003495-200161020-00011 McClellan, K. & Perry, C. M. Oseltamivir: a review of its use in influenza. Drugs 61, 263-283 (2001).
J. Pharmacol. Exp. Ther. D Shi 319 1477 2006 10.1124/jpet.106.111807 Shi, D. et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 319, 1477-1484 (2006).
Drug Metab. Dispos. UG Eriksson 31 294 2003 10.1124/dmd.31.3.294 Eriksson, U. G. et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 31, 294-305 (2003).
Drug Metab. Dispos. B Clement 31 645 2003 10.1124/dmd.31.5.645 Clement, B. & Lopian, K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab. Dispos. 31, 645-651 (2003).
Thromb. Res. D Gustafsson 101 171 2001 10.1016/S0049-3848(00)00399-6 Gustafsson, D. et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101, 171-181 (2001).
Nature Rev. Drug Discov. S Frantz 6 5 2007 10.1038/nrd2230 Frantz, S. Pharma faces major challenges after a year of failures and heated battles. Nature Rev. Drug Discov. 6, 5-7 (2007).
AAPS PharmSci HK Han 2 e6 2000 10.1208/ps020106 Han, H. K. & Amidon, G. L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2, e6 (2000).
Expert Opin. Biol. Ther. C Yang 1 159 2001 10.1517/14712598.1.2.159 Yang, C., Tirucherai, G. S. & Mitra, A. K. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther. 1, 159-175 (2001).
Biochem. Biophys. Res. Commun. PV Balimane 250 246 1998 10.1006/bbrc.1998.9298 Balimane, P. V. et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250, 246-251 (1998).
J. Pharmacol. Exp. Ther. RL de Vrueh 286 1166 1998 de Vrueh, R. L., Smith, P. L. & Lee, C. P. Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J. Pharmacol. Exp. Ther. 286, 1166-1170 (1998).
J. Pharmacol. Exp. Ther. A Guo 289 448 1999 Guo, A., Hu, P., Balimane, P. V., Leibach, F. H. & Sinko, P. J. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 289, 448-454 (1999).
J. Pharm. Sci. M Sugawara 89 781 2000 10.1002/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7 Sugawara, M. et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89, 781-789 (2000).
J. Pharmacol. Exp. Ther. M Tsuda 318 455 2006 10.1124/jpet.106.102830 Tsuda, M. et al. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J. Pharmacol. Exp. Ther. 318, 455-460 (2006).
Pharm. Res. H Han 15 1154 1998 10.1023/A:1011919319810 Han, H. et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15, 1154-1159 (1998).
J. Biol. Chem. I Kim 278 25348 2003 10.1074/jbc.M302055200 Kim, I. et al. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 278, 25348-25356 (2003).
Expert Opin. Pharmacother. DN Cruz 1 835 2000 10.1517/14656566.1.4.835 Cruz, D. N. Midodrine: a selective α-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin. Pharmacother. 1, 835-840 (2000).
J. Pharmacol. Exp. Ther. KC Cundy 311 324 2004 10.1124/jpet.104.067959 Cundy, K. C. et al. XP13512 [(+/-)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther. 311, 324-333 (2004).
J. Pharmacol. Exp. Ther. KC Cundy 311 315 2004 10.1124/jpet.104.067934 Cundy, K. C. et al. XP13512 [(+/-)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther. 311, 315-323 (2004).
Pharmacotherapy BA Boucher 16 777 1996 10.1002/j.1875-9114.1996.tb02996.x Boucher, B. A. Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy 16, 777-791 (1996).
Neurology TR Browne 46 S3 1996 10.1212/WNL.46.6_Suppl_1.3S Browne, T. R., Kugler, A. R. & Eldon, M. A. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 46, S3-S7 (1996).
J. Pharm. Sci. SA Varia 73 1068 1984 10.1002/jps.2600730812 Varia, S. A., Schuller, S., Sloan, K. B. & Stella, V. J. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73, 1068-1073 (1984).
Crit. Rev. Toxicol. HD Heck 20 397 1990 10.3109/10408449009029329 Heck, H. D., Casanova, M. & Starr, T. B. Formaldehyde toxicity - new understanding. Crit. Rev. Toxicol. 20, 397-426 (1990).
Org. Proc. Res. Develop. A Bentley 6 109 2002 10.1021/op010064+ Bentley, A. et al. The discovery and process. Development of a commercial route to the water soluble prodrug, Fosfluconazole. Org. Proc. Res. Develop. 6, 109-112 (2002).
J. Clin. Pharmacol. S Sobue 44 284 2004 10.1177/0091270003262799 Sobue, S., Sekiguchi, K., Shimatani, K. & Tan, K. Pharmacokinetics and safety of Fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers. J. Clin. Pharmacol. 44, 284-292 (2004).
Eur. J. Anaesthesiol. M Schywalsky 20 182 2003 10.1097/00003643-200303000-00002 Schywalsky, M. et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur. J. Anaesthesiol. 20, 182-190 (2003).
Anesth. Analg. MG Banaszczyk 95 1285 2002 10.1097/00000539-200211000-00034 Banaszczyk, M. G. et al. Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. Anesth. Analg. 95, 1285-1292 (2002).
Pharm. Res. M Safadi 10 1350 1993 10.1023/A:1018934200343 Safadi, M., Oliyai, R. & Stella, V. J. Phosphoryloxymethyl carbamates and carbonates - novel water-soluble prodrugs for amines and hindered alcohols. Pharm. Res. 10, 1350-1355 (1993).
Nature Struct. Biol. S Bencharit 9 337 2002 10.1038/nsb790 Bencharit, S. et al. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nature Struct. Biol. 9, 337-342 (2002).
Drug Metab. Dispos. SP Sanghani 32 505 2004 10.1124/dmd.32.5.505 Sanghani, S. P. et al. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab. Dispos. 32, 505-511 (2004).
Drug Metab. Dispos. JG Slatter 25 1157 1997 Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J. & Wienkers, L. C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25, 1157-1164 (1997).
Oncologist ML Rothenberg 6 66 2001 10.1634/theoncologist.6-1-66 Rothenberg, M. L. Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 6, 66-80 (2001).
Br. J. Cancer S Guichard 80 364 1999 10.1038/sj.bjc.6690364 Guichard, S. et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br. J. Cancer 80, 364-370 (1999).
Drug Metab. Dispos. JG Slatter 28 423 2000 Slatter, J. G. et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos. 28, 423-433 (2000).
M Hageman 571 2007 Prodrugs: Challenges and Rewards Hageman, M. & Morozowich, W. in Prodrugs: Challenges and Rewards. Part 2 (eds Stella, V. J., Hageman, M., Oliyai, R., Tilley, J. & Maag, H.) 571-579 (AAPS Press/Springer, Arlington, Virginia, 2007).
Adv. Drug Deliv. Rev. T Järvinen 19 203 1996 10.1016/0169-409X(95)00107-I Järvinen, T. & Järvinen, K. Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 19, 203-224 (1996).
J. Pharm. Sci. A Hussain 65 1510 1976 10.1002/jps.2600651023 Hussain, A. & Truelove, J. E. Prodrug approaches to enhancement of physicochemical properties of drugs IV: novel epinephrine prodrug. J. Pharm. Sci. 65, 1510-1512 (1976).
Arch. Ophthalmol. JA Anderson 98 350 1980 10.1001/archopht.1980.01020030346024 Anderson, J. A. Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch. Ophthalmol. 98, 350-353 (1980).
Ophthalmology AI Mandell 85 268 1978 10.1016/S0161-6420(78)35668-2 Mandell, A. I., Stentz, F. & Kitabchi, A. E. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology 85, 268-275 (1978).
Invest. Ophthalmol. Vis. Sci. CP Wei 17 315 1978 Wei, C. P., Anderson, J. A. & Leopold, I. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest. Ophthalmol. Vis. Sci. 17, 315-321 (1978).
Am. J. Ophthalmol. MB Kaback 81 768 1976 10.1016/0002-9394(76)90360-3 Kaback, M. B., Podos, S. M., Harbin, T. S. Jr, Mandell, A. & Becker, B. The effects of dipivalyl epinephrine on the eye. Am. J. Ophthalmol. 81, 768-772 (1976).
Am. J. Ophthalmol. AN Kohn 87 196 1979 10.1016/0002-9394(79)90142-9 Kohn, A. N. et al. Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. Am. J. Ophthalmol. 87, 196-201 (1979).
J. Ocul. Pharmacol. Ther. MR Hellberg 19 97 2003 10.1089/108076803321637627 Hellberg, M. R. et al. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2α by human and rabbit ocular tissue. J. Ocul. Pharmacol. Ther. 19, 97-103 (2003).
Am. J. Ophthalmol. PA Netland 132 472 2001 10.1016/S0002-9394(01)01177-1 Netland, P. A. et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132, 472-484 (2001).
J. Ocul. Pharmacol. Ther. NA Sharif 19 501 2003 10.1089/108076803322660422 Sharif, N. A., Kelly, C. R., Crider, J. Y., Williams, G. W. & Xu, S. X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19, 501-515 (2003).
Surv. Ophthalmol. R Susanna Jr. 47 Suppl. 1 97 2002 10.1016/S0039-6257(02)00308-9 Susanna, R., Jr., Chew, P. & Kitazawa, Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv. Ophthalmol. 47 (Suppl. 1), 97-104 (2002).
Med. Res. Rev. KB Sloan 23 763 2003 10.1002/med.10048 Sloan, K. B. & Wasdo, S. Designing for topical delivery: prodrugs can make the difference. Med. Res. Rev. 23, 763-793 (2003).
Pharm. Res. KB Sloan 23 2729 2006 10.1007/s11095-006-9108-0 Sloan, K. B., Wasdo, S. C. & Rautio, J. Design for optimized topical delivery: Prodrugs and a paradigm change. Pharm. Res. 23, 2729-2747 (2006). Offers useful directives for the design of drugs or prodrugs for optimized topical delivery.
Eur. J. Pharm. Sci. J Rautio 11 157 2000 10.1016/S0928-0987(00)00090-7 Rautio, J. et al. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur. J. Pharm. Sci. 11, 157-163 (2000).
J. Med. Chem. J Rautio 43 1489 2000 10.1021/jm991149s Rautio, J. et al. Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery. J. Med. Chem. 43, 1489-1494 (2000).
Br. J. Dermatol. RA Chandraratna 135 Suppl. 49 18 1996 10.1111/j.1365-2133.1996.tb15662.x Chandraratna, R. A. Tazarotene - first of a new generation of receptor-selective retinoids. Br. J. Dermatol. 135 (Suppl. 49), 18-25 (1996).
Am. J. Clin. Dermatol. TM Dando 6 255 2005 10.2165/00128071-200506040-00006 Dando, T. M. & Wellington, K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am. J. Clin. Dermatol. 6, 255-272 (2005).
Drugs RH Foster 55 705 1998 10.2165/00003495-199855050-00008 Foster, R. H., Brogden, R. N. & Benfield, P. Tazarotene. Drugs 55, 705-711 (1998).
J. Am. Acad. Dermatol. R Marks 37 S25 1997 10.1016/S0190-9622(97)80397-0 Marks, R. Clinical safety of tazarotene in the treatment of plaque psoriasis. J. Am. Acad. Dermatol. 37, S25-S32 (1997).
Clin. Pharmacokinet. DD Tang-Liu 37 273 1999 10.2165/00003088-199937040-00001 Tang-Liu, D. D., Matsumoto, R. M. & Usansky, J. I. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin. Pharmacokinet. 37, 273-287 (1999).
Neurology JG Nutt 36 739 1986 10.1212/WNL.36.6.739 Nutt, J. G. & Woodward, W. R. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36, 739-744 (1986).
N. Engl. J. Med. JG Nutt 310 483 1984 10.1056/NEJM198402233100802 Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H. & Anderson, J. L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J. Med. 310, 483-488 (1984).
Adv. Drug Deliv. Rev. BD Anderson 19 171 1996 10.1016/0169-409X(95)00106-H Anderson, B. D. Prodrugs for improved CNS delivery. Adv. Drug Deliv. Rev. 19, 171-202 (1996).
Exp. Opin. Ther. Pat. EW Damen 11 651 2001 10.1517/13543776.11.4.651 Damen, E. W., Groot, F. M. & Scheeren, H. W. Novel anthracyclin prodrugs. Exp. Opin. Ther. Pat. 11, 651-666 (2001).
Curr. Med. Chem. FM de Groot 8 1093 2001 10.2174/0929867013372634 de Groot, F. M., Damen, E. W. & Scheeren, H. W. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr. Med. Chem. 8, 1093-1122 (2001).
Adv. Drug Deliv. Rev. A Shinhababu 19 241 1996 10.1016/0169-409X(95)00109-K Shinhababu, A. & Thakker, D. Prodrug of anticancer agents. Adv. Drug Deliv. Rev. 19, 241-273 (1996).
J. Pharmacol. Exp. Ther. SK Quinney 313 1011 2005 10.1124/jpet.104.081265 Quinney, S. K. et al. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J. Pharmacol. Exp. Ther. 313, 1011-1016 (2005).
Clin. Ther. CM Walko 27 23 2005 10.1016/j.clinthera.2005.01.005 Walko, C. M. & Lindley, C. Capecitabine: a review. Clin. Ther. 27, 23-44 (2005).
Eur. J. Cancer M Miwa 34 1274 1998 10.1016/S0959-8049(98)00058-6 Miwa, M. et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34, 1274-1281 (1998).
Eur. J. Cancer M Venturini 38 Suppl. 2 3 2002 10.1016/S0959-8049(01)00414-2 Venturini, M. Rational development of capecitabine. Eur. J. Cancer 38 (Suppl. 2), 3-9 (2002).
Expert Opin. Biol. Ther. KD Bagshawe 4 1777 2004 10.1517/14712598.4.11.1777 Bagshawe, K. D., Sharma, S. K. & Begent, R. H. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin. Biol. Ther. 4, 1777-1789 (2004).
Curr. Opin. Investig. Drugs SK Sharma 6 611 2005 Sharma, S. K., Bagshawe, K. D. & Begent, R. H. Advances in antibody-directed enzyme prodrug therapy. Curr. Opin. Investig. Drugs 6, 611-615 (2005). This review summarizes the recent progress of ADEPT for cancer treatment.
Bioconjug. Chem. I Niculescu-Duvaz 9 4 1998 10.1021/bc970116t Niculescu-Duvaz, I., Spooner, R., Marais, R. & Springer, C. J. Gene-directed enzyme prodrug therapy. Bioconjug. Chem. 9, 4-22 (1998).
Anticancer Drugs GU Dachs 16 349 2005 10.1097/00001813-200504000-00001 Dachs, G. U., Tupper, J. & Tozer, G. M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16, 349-359 (2005). This review describes seven of the most utilized GDEPT systems in vitro and in vivo.
Tumour Biol. K Chester 25 91 2004 10.1159/000077727 Chester, K. et al. Engineering antibodies for clinical applications in cancer. Tumour Biol. 25, 91-98 (2004).
Br. J. Cancer RJ Francis 87 600 2002 10.1038/sj.bjc.6600517 Francis, R. J. et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer 87, 600-607 (2002).
Clin. Cancer Res. MP Napier 6 765 2000 Napier, M. P. et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 6, 765-772 (2000).
Curr. Drug Metab. JE van Montfoort 4 185 2003 10.2174/1389200033489460 van Montfoort, J. E. et al. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4, 185-211 (2003).
Curr. Opin. Investig. Drugs MD Erion 7 109 2006 Erion, M. D., Bullough, D. A., Lin, C. C. & Hong, Z. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr. Opin. Investig. Drugs 7, 109-117 (2006).
J. Am. Chem. Soc. MD Erion 126 5154 2004 10.1021/ja031818y Erion, M. D. et al. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126, 5154-5163 (2004).
Clin. Pharmacokinet. VF Mauro 24 195 1993 10.2165/00003088-199324030-00002 Mauro, V. F. Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 24, 195-202 (1993).
Pharmacol. Ther. Y Shitara 112 71 2006 10.1016/j.pharmthera.2006.03.003 Shitara, Y. & Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71-105 (2006).
Pharmacol. Ther. CR Sirtori 60 431 1993 10.1016/0163-7258(93)90031-8 Sirtori, C. R. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol. Ther. 60, 431-459 (1993).
Clin. Pharmacol. Ther. PJ Neuvonen 80 565 2006 10.1016/j.clpt.2006.09.003 Neuvonen, P. J., Niemi, M. & Backman, J. T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581 (2006).
Drugs AC Altamura 63 493 2003 10.2165/00003495-200363050-00004 Altamura, A. C. et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 63, 493-512 (2003).
J. Pharmacol. Exp. Ther. CF Minto 281 93 1997 Minto, C. F., Howe, C., Wishart, S., Conway, A. J. & Handelsman, D. J. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 281, 93-102 (1997).
Schizophr. Res. SR Marder 53 25 2002 10.1016/S0920-9964(00)00184-5 Marder, S. R. et al. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr. Res. 53, 25-30 (2002).
Drug Metab. Rev. L Svensson 19 165 1988 10.3109/03602538809049622 Svensson, L. & Tunek, A. The design and bioactivation of presystemically stable prodrugs. Drug Metab. Rev. 19, 165-194 (1988).
Biochem. Pharmacol. A Tunek 37 3867 1988 10.1016/0006-2952(88)90068-8 Tunek, A., Levin, E. & Svensson, L. Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem. Pharmacol. 37, 3867-3876 (1988).
Curr. Therap. Res. G Persson 56 457 1995 10.1016/0011-393X(95)85078-3 Persson, G., Pahlm, O. & Gnosspelius, Y. Oral bambuterol versus terbutaline in patients with asthma. Curr. Therap. Res. 56, 457-465 (1995).
S Grossman 411 2007 Prodrugs: Challenges and Rewards Grossman, S. in Prodrugs: Challenges and Rewards. Part 2 (eds. Stella, V. J. et al.) 411-424 (AAPS/Springer, New York, 2007).
Pharmacol. Rev. EP Brass 54 589 2002 10.1124/pr.54.4.589 Brass, E. P. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol. Rev. 54, 589-598 (2002).
Drug Metab. Dispos. KC Kwan 25 1329 1997 Kwan, K. C. Oral bioavailability and first-pass effects. Drug Metab. Dispos. 25, 1329-1336 (1997).
Expert Opin. Drug Metab. Toxicol. VH Thomas 2 591 2006 10.1517/17425255.2.4.591 Thomas, V. H. et al. The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol. 2, 591-608 (2006).
Y Kwon 2001 Handbook of Essential Pharmacokinetics, Pharmacokinetics, and Drug Metabolism for Industrial Scientists Kwon, Y. Handbook of Essential Pharmacokinetics, Pharmacokinetics, and Drug Metabolism for Industrial Scientists (Springer-Verlag, New York, 2001).
J. Pharmacokinet. Biopharm. H Boxenbaum 8 165 1980 10.1007/BF01065191 Boxenbaum, H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm. 8, 165-176 (1980).
Drugs PA Todd 31 198 1986 10.2165/00003495-198631030-00002 Todd, P. A. & Heel, R. C. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31, 198-248 (1986).
J. Pharmacokinet. Biopharm. M Ehrnebo 7 429 1979 10.1007/BF01062386 Ehrnebo, M., Nilsson, S. O. & Boreus, L. O. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. J. Pharmacokinet. Biopharm. 7, 429-451 (1979).
J. Pharm. Sci. WJ Jusko 62 69 1973 10.1002/jps.2600620112 Jusko, W. J. & Lewis, G. P. Comparison of ampicillin and hetacillin pharmacokinetics in man. J. Pharm. Sci. 62, 69-76 (1973).
Antimicrob. Agents Chemother. RAV Hodge 33 1765 1989 10.1128/AAC.33.10.1765 Hodge, R. A. V., Sutton, D., Boyd, M. R., Harnden, M. R. & Jarvest, R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33, 1765-1773 (1989).
Drugs D Simpson 66 2397 2006 10.2165/00003495-200666180-00016 Simpson, D. & Lyseng-Williamson, K. A. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 66, 2397-2416 (2006).
OS Gudmundsson 531 2007 Prodrugs: Challenges and Rewards Gudmundsson, O. S. & Antman, M. in Prodrugs: Challenges and Rewards. Part 2 (eds Stella, V. J. et al.) 531-539 (AAPS Press/Springer, New York, 2007).
Clin. Pharmacokinet. AT Bergenheim 34 163 1998 10.2165/00003088-199834020-00004 Bergenheim, A. T. & Henriksson, R. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin. Pharmacokinet. 34, 163-172 (1998).
Drugs Aging CM Perry 7 49 1995 10.2165/00002512-199507010-00006 Perry, C. M. & McTavish, D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7, 49-74 (1995).
CLAO J. F Sousa 17 282 1991 Sousa, F. The bioavailability and therapeutic effectiveness of prednisolone acetate vs. prednisolone sodium phosphate: a 20-year review. CLAO J. 17, 282-284 (1991).
J. Clin. Oncol. MA Boogaerts 19 4252 2001 10.1200/JCO.2001.19.22.4252 Boogaerts, M. A. et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 19, 4252-4258 (2001).
Drugs CM Perry 52 754 1996 10.2165/00003495-199652050-00009 Perry, C. M. & Faulds, D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52, 754-772 (1996).
Ann. Pharmacother. JM Cocohoba 36 1075 2002 10.1345/aph.1A393 Cocohoba, J. M. & McNicholl, I. R. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann. Pharmacother. 36, 1075-1079 (2002).
Expert Opin. Investig. Drugs P Reusser 10 1745 2001 10.1517/13543784.10.9.1745 Reusser, P. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin. Investig. Drugs 10, 1745-1753 (2001).
Stella, V. J., Zygmunt, J. J, Georg, I. G. & Muhammed, S. Water soluble prodrugs of hindered alcohols or phenols. US19980131385 (2005).
T Jarvinen 125 2007 Prodrugs: Challenges and Rewards 10.1007/978-0-387-49785-3_4 Jarvinen, T. & Niemi, R. in Prodrugs: Challenges and Rewards. Part 1 (eds Stella, V. J. et al.) 125-155 (AAPS Press/Springer, New York, 2007).
J. Pharmacol. Exp. Ther. MD Erion 312 554 2005 10.1124/jpet.104.075903 Erion, M. D. et al. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312, 554-560 (2005).
Ann. Pharmacother. VF Mauro 25 257 1991 Mauro, V. F. & MacDonald, J. L. Simvastatin: a review of its pharmacology and clinical use. Ann. Pharmacother. 25, 257-264 (1991).
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.